Department of Radiation Oncology, New York University School of Medicine, New York, New York.
Department of Surgery, New York University School of Medicine, New York, New York.
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):899-906. doi: 10.1016/j.ijrobp.2014.03.036. Epub 2014 May 24.
To report the 5-year results of a technique of prone breast radiation therapy delivered by a regimen of accelerated intensity modulated radiation therapy with a concurrent boost to the tumor bed.
Between 2003 and 2006, 404 patients with stage I-II breast cancer were prospectively enrolled into 2 consecutive protocols, institutional trials 03-30 and 05-181, that used the same regimen of 40.5 Gy/15 fractions delivered to the index breast over 3 weeks, with a concomitant daily boost to the tumor bed of 0.5 Gy (total dose 48 Gy). All patients were treated after segmental mastectomy and had negative margins and nodal assessment. Patients were set up prone: only if lung or heart volumes were in the field was a supine setup attempted and chosen if found to better spare these organs.
Ninety-two percent of patients were treated prone, 8% supine. Seventy-two percent had stage I, 28% stage II invasive breast cancer. In-field lung volume ranged from 0 to 228.27 cm(3), mean 19.65 cm(3). In-field heart volume for left breast cancer patients ranged from 0 to 21.24 cm(3), mean 1.59 cm(3). There was no heart in the field for right breast cancer patients. At a median follow-up of 5 years, the 5-year cumulative incidence of isolated ipsilateral breast tumor recurrence was 0.82% (95% confidence interval [CI] 0.65%-1.04%). The 5-year cumulative incidence of regional recurrence was 0.53% (95% CI 0.41%-0.69%), and the 5-year overall cumulative death rate was 1.28% (95% CI 0.48%-3.38%). Eighty-two percent (95% CI 77%-85%) of patients judged their final cosmetic result as excellent/good.
Prone accelerated intensity modulated radiation therapy with a concomitant boost results in excellent local control and optimal sparing of heart and lung, with good cosmesis. Radiation Therapy Oncology Group protocol 1005, a phase 3, multi-institutional, randomized trial is ongoing and is evaluating the equivalence of a similar dose and fractionation approach to standard 6-week radiation therapy with a sequential boost.
报告一种通过加速强度调制放射治疗方案和肿瘤床同步推量来进行俯卧位乳房放射治疗的 5 年结果。
在 2003 年至 2006 年期间,404 名 I 期-II 期乳腺癌患者前瞻性地入组了两项连续的方案,即机构试验 03-30 和 05-181,这些方案均使用相同的方案,即 3 周内给予 40.5 Gy/15 次的指数乳房照射,同时每日给予肿瘤床 0.5 Gy 的同步推量(总剂量 48 Gy)。所有患者均在接受区段乳房切除术治疗后进行治疗,且均有阴性切缘和淋巴结评估。患者采用俯卧位设置:仅当肺部或心脏体积在照射野内时,才尝试采用仰卧位设置,如果发现这样可以更好地保护这些器官,则选择仰卧位设置。
92%的患者采用俯卧位治疗,8%采用仰卧位治疗。72%的患者为 I 期,28%为 II 期浸润性乳腺癌。在野肺体积范围为 0 至 228.27 cm³,平均值为 19.65 cm³。左乳腺癌患者的在野心脏体积范围为 0 至 21.24 cm³,平均值为 1.59 cm³。右乳腺癌患者的心脏不在照射野内。在中位随访 5 年时,5 年无复发生存率的累积发生率为 0.82%(95%置信区间 [CI] 0.65%-1.04%)。5 年区域复发累积发生率为 0.53%(95% CI 0.41%-0.69%),5 年总死亡率为 1.28%(95% CI 0.48%-3.38%)。82%(95% CI 77%-85%)的患者认为他们的最终美容效果为优秀/良好。
采用俯卧位加速强度调制放射治疗并进行肿瘤床同步推量可获得良好的局部控制效果,并能使心脏和肺部得到最佳保护,美容效果良好。放射治疗肿瘤学组 1005 号方案是一项正在进行的、多机构、随机的 III 期临床试验,正在评估类似剂量和分割方法与标准 6 周放射治疗加序贯推量的等效性。